Evidence map›Paper›PMID 33217974›Full record

ArticleJournal of personalized medicine2020

Evaluation of the Role of Circulating Tumor Cells and Microsatellite Instability Status in Predicting Outcome of Advanced CRC Patients.

Ippokratis Messaritakis, Maria Sfakianaki, Konstantinos Vogiatzoglou, Asimina Koulouridi, Chara Koutoulaki, Dimitrios Mavroudis, Maria Tzardi, Nikolaos Gouvas, John Tsiaoussis, John Souglakos

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Circulating tumor cells: biology and clinical significance.Signal transduction and targeted therapy · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Ippokratis MessaritakisLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.ORCID 0000-0003-1877-500X
Maria SfakianakiLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.
Konstantinos VogiatzoglouLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.
Asimina KoulouridiLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.
Chara KoutoulakiLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.
Dimitrios MavroudisLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.
Maria TzardiLaboratory of Pathology, University General Hospital of Heraklion, 70013 Heraklion, Greece.
Nikolaos GouvasMedical School, University of Cyprus, 20537 Nicosia, Cyprus.
John TsiaoussisDepartment of Anatomy, School of Medicine, University of Crete, 70013 Heraklion, Greece.
John SouglakosLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.
University of Crete · GRUniversity Hospital of Heraklion · GRUniversity of Cyprus · CY

Funding

Gastrointestinal Cancer Study Group N/AHellenic Society of Medical Oncology N/A
6 · The paper itself

Abstract

Colorectal cancer (CRC) remains one of the leading causes of cancer-related death due to its high metastatic potential. This study aimed to investigate the detection and heterogeneity of circulating tumor cells (CTCs) and the microsatellite instability (MSI) status in advanced CRC patients prior to any systemic front-line treatment. Peripheral whole blood was obtained from 198 patients. CTCs were detected using double immunofluorescence and a real time-polymerase chain reaction assay; whereas MSI status was evaluated using fragment analysis. Median age of the patients was 66 years, 63.1% were males, 65.2% had a colon/sigmoid tumor location and 90.4% had a good performance status (PS). MSI-High status was detected in 4.9% of the patients; 33.3%, 56.1% and 8.6% patients had at least one detectable CEACAM5

Indexed as

CEACAM5colorectal cancerCTCsmetastaticmicrosatellite instability

Identifiers

PMID33217974
PMCPMC7712177
OpenAlexW3105708527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.